Andrew W. Roberts, MBBS, PhD

Metcalf Chair of Leukaemia Research
Royal Melbourne Hospital & Peter MacCallum Cancer Centre
Melbourne, Australia

NA

Presentation(s):

• (1553093) Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon

  Friday, October 6, 2023
  1:30 PM – 1:40 PM EDT